Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program

被引：0
|
作者：
Jeroen, de Filette [1 ]
Yanina, Jansen [2 ]
Max, Schreuer [2 ]
Hendrik, Everaert [3 ]
Brigitte, Velkeniers [1 ]
Bart, Neyns [2 ]
Bert, Bravenboer [1 ]
机构：
[1] VUB, Univ Ziekenhuis Brussel, Dept Endocrinol, Laarbeeklaan 101, B-1090 Brussels, Belgium
[2] VUB, Univ Ziekenhuis Brussel, Med Oncol, Laarbeeklaan 101, B-1090 Brussels, Belgium
[3] VUB, Univ Ziekenhuis Brussel, Nucl Med, Laarbeeklaan 101, B-1090 Brussels, Belgium
来源：
ACTA CLINICA BELGICA | 2016年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [31] IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH TREMELIMUMAB (CP-675,206)
    Wallis, N.
    Bulanhagui, C. A.
    ElSawah, G.
    Pavlov, D.
    Gomez-Navarro, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 242 - 242
  • [32] Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
    Albarran-Artahona, Victor
    Laguna, Juan-Carlos
    Gorria, Teresa
    Torres-Jimenez, Javier
    Pascal, Mariona
    Mezquita, Laura
    DIAGNOSTICS, 2022, 12 (09)
  • [33] Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
    Kawai, Taketo
    Sato, Yusuke
    Makino, Katsuhiro
    Yamada, Yuta
    Nomiya, Akira
    Nakamura, Masaki
    Yamada, Daisuke
    Suzuki, Motofumi
    Igawa, Yasuhiko
    Kume, Haruki
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 114 - 115
  • [34] Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database
    Tan, Feilong
    Zhou, Li
    Huang, Guijiang
    Li, Yanhua
    Yin, Wenjie
    Xia, Hongying
    ONCOLOGY, 2025,
  • [35] Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
    Euvrard, Romain
    Robert, Marie
    Mainbourg, Sabine
    Dalle, Stephane
    Lega, Jean-Christophe
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 (02) : 369 - 379
  • [36] Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
    Bisschop, Cornelis
    Wind, Thijs T.
    Blank, Christian U.
    Koornstra, Rutger H. T.
    Kapiteijn, Ellen
    Van den Eertwegh, Alfonsus J. M.
    De Groot, Jan Willem B.
    Jalving, Mathilde
    Hospers, Geke A. P.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (06) : 208 - 214
  • [37] Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1667 - 1668
  • [38] Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
    Ando, Takayuki
    Ueda, Akira
    Ogawa, Kohei
    Motoo, Iori
    Kajiura, Shinya
    Nakajima, Takahiko
    Hirano, Katsuhisa
    Okumura, Tomoyuki
    Tsukada, Kenichiro
    Hara, Takuo
    Suzuki, Nobuhiro
    Nakada, Naokatsu
    Horikawa, Naoki
    Fujii, Tsutomu
    Yasuda, Ichiro
    IN VIVO, 2021, 35 (01): : 475 - 482
  • [39] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
  • [40] Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Liang, Yao
    Maeda, Osamu
    Ando, Yuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, : 365 - 375
12345